These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 24142036

  • 1. Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates.
    de Castilla DL, Rakita RM, Spitters CE, Narita M, Jain R, Limaye AP.
    Transplantation; 2014 Jan 27; 97(2):206-11. PubMed ID: 24142036
    [Abstract] [Full Text] [Related]

  • 2. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
    Simkins J, Abbo LM, Camargo JF, Rosa R, Morris MI.
    Transplantation; 2017 Jun 27; 101(6):1468-1472. PubMed ID: 27548035
    [Abstract] [Full Text] [Related]

  • 3. Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates.
    Knoll BM, Nog R, Wu Y, Dhand A.
    Infection; 2017 Jun 27; 45(3):335-339. PubMed ID: 28276008
    [Abstract] [Full Text] [Related]

  • 4. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
    Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, Skidmore B, Alvarez GG.
    Pharmacoepidemiol Drug Saf; 2018 Jun 27; 27(6):557-566. PubMed ID: 29573031
    [Abstract] [Full Text] [Related]

  • 5. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2011 Dec 09; 60(48):1650-3. PubMed ID: 22157884
    [Abstract] [Full Text] [Related]

  • 6. Use of Rifapentine and Isoniazid Directly Observed Therapy for the Treatment of Latent Tuberculosis Infection in a Military Clinic.
    Jinbo J, Lustik M, West GF, Kloetzel M.
    Mil Med; 2017 Sep 09; 182(9):e2024-e2029. PubMed ID: 28885972
    [Abstract] [Full Text] [Related]

  • 7. Treatment of latent tuberculosis infection: An update.
    Lobue P, Menzies D.
    Respirology; 2010 May 09; 15(4):603-22. PubMed ID: 20409026
    [Abstract] [Full Text] [Related]

  • 8. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW, Yang SF, Yeh YP, Tsao TC, Tsao SM.
    Medicine (Baltimore); 2016 Aug 09; 95(34):e4126. PubMed ID: 27559940
    [Abstract] [Full Text] [Related]

  • 9. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY, Huang YW, Huang WC, Chang LY, Chan PC, Chuang YC, Ruan SY, Wang JY, Wang JT.
    Tuberculosis (Edinb); 2018 Jul 09; 111():121-126. PubMed ID: 30029896
    [Abstract] [Full Text] [Related]

  • 10. High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons.
    Schmit KM, Lobato MN, Lang SG, Wheeler S, Kendig NE, Bur S.
    J Public Health Manag Pract; 2019 Jul 09; 25(2):E1-E6. PubMed ID: 30024493
    [Abstract] [Full Text] [Related]

  • 11. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
    Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Miró JM, Villarino ME, Weiner M, Borisov AS, TB Trials Consortium iAdhere Study Team.
    Ann Intern Med; 2017 Nov 21; 167(10):689-697. PubMed ID: 29114781
    [Abstract] [Full Text] [Related]

  • 12. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.
    Bock NN, Sterling TR, Hamilton CD, Pachucki C, Wang YC, Conwell DS, Mosher A, Samuels M, Vernon A, Tuberculosis Trials Consortium, Centers for Disease Control and Prevention, Atlanta, Georgia.
    Am J Respir Crit Care Med; 2002 Jun 01; 165(11):1526-30. PubMed ID: 12045127
    [Abstract] [Full Text] [Related]

  • 13. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
    Tseng SY, Huang YS, Chang TE, Perng CL, Huang YH.
    J Chin Med Assoc; 2021 Nov 01; 84(11):993-1000. PubMed ID: 34747900
    [Abstract] [Full Text] [Related]

  • 14. Improving Treatment Completion Rates for Latent Tuberculosis Infection: A Review of Two Treatment Regimens at a Community Health Center.
    Lines G, Hunter P, Bleything S.
    J Health Care Poor Underserved; 2015 Nov 01; 26(4):1428-39. PubMed ID: 26548690
    [Abstract] [Full Text] [Related]

  • 15. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
    Lin SY, Chiu YW, Lu PL, Hwang SJ, Chen TC, Hsieh MH, Chen YH.
    J Microbiol Immunol Infect; 2019 Feb 01; 52(1):158-162. PubMed ID: 29907535
    [Abstract] [Full Text] [Related]

  • 16. Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center.
    Arguello Perez E, Seo SK, Schneider WJ, Eisenstein C, Brown AE.
    Clin Infect Dis; 2017 Nov 29; 65(12):2105-2111. PubMed ID: 29020308
    [Abstract] [Full Text] [Related]

  • 17. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
    Surey J, Stagg HR, Yates TA, Lipman M, White PJ, Charlett A, Muñoz L, Gosce L, Rangaka MX, Francis M, Hack V, Kunst H, Abubakar I.
    BMC Infect Dis; 2021 Jan 21; 21(1):90. PubMed ID: 33478428
    [Abstract] [Full Text] [Related]

  • 18. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.
    Cook PP, Maldonado RA, Yarnell CT, Holbert D.
    Clin Infect Dis; 2006 Aug 01; 43(3):271-5. PubMed ID: 16804838
    [Abstract] [Full Text] [Related]

  • 19. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
    Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME, TB Trials Consortium.
    Int J Tuberc Lung Dis; 2015 Sep 01; 19(9):1039-44, i-v. PubMed ID: 26260821
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE, Bass S, Srinivas P, Miranda C, Johnson L, Pallotta AM.
    Ann Pharmacother; 2020 May 01; 54(5):457-463. PubMed ID: 31729245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.